EP0826062A1 - Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci - Google Patents

Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci

Info

Publication number
EP0826062A1
EP0826062A1 EP96914852A EP96914852A EP0826062A1 EP 0826062 A1 EP0826062 A1 EP 0826062A1 EP 96914852 A EP96914852 A EP 96914852A EP 96914852 A EP96914852 A EP 96914852A EP 0826062 A1 EP0826062 A1 EP 0826062A1
Authority
EP
European Patent Office
Prior art keywords
hbv
cells
vector according
proteins
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96914852A
Other languages
German (de)
English (en)
Inventor
Peter Hofschneider
Peter Habenberger
Ludwig Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mondogen GmbH
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of EP0826062A1 publication Critical patent/EP0826062A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • HBV vectors and cells for their delivery are examples of HBV vectors and cells for their delivery
  • the invention relates to HBV vectors, methods for their provision and cells that can be used therefor, and the use of the HBV vectors.
  • the strict organ specificity of the vector system used is an essential requirement.
  • the hepatocytes of the liver are of particular interest for this.
  • the liver is the source of most serum proteins and plays a central role in the regulation of metabolism in the peripheral organs. This is why a large number of different, hereditary metabolic defects are manifested in the liver.
  • the liver is also affected by some viral infections that are difficult to treat.
  • the liver could be used as a bioreactor for the secretion of various proteins, provided that there is a suitable gene transfer system. This could also break new ground in the treatment of diseases that do not manifest in the liver.
  • liver cell-specific gene transfer system that could be used in vivo.
  • the present invention is therefore based on the object of a gene transfer system To provide stem that is liver cell specific and is suitable for in vivo gene therapy.
  • the present invention thus relates to an HBV vector in which HBV functional genes are at least partially deleted.
  • HBV indicates hepatitis B virus. This is a DNA virus with a genome length of 3.2 kb.
  • the hepatitis B virus genome contains four partially overlapping open reading frames (ORF): the Pol-ORF (HBV polymerase), the S-ORFs (surface proteins), the C-ORFs (capsid proteins) and the X-ORF (viral transactivator) .
  • ORF open reading frames
  • HBV vector encompasses any HBV vector which is suitable for gene transfer, particularly in the case of gene therapy, very particularly in the case of in vivo gene therapy.
  • vector relates to a DNA molecule as well as a virus particle.
  • the genes for the polymerase, the surface proteins and the capsid proteins of HBV are at least partially deleted in an HBV vector according to the invention. It is particularly advantageous if these genes are completely deleted. It is furthermore advantageous if the gene of the HBV transactivator is also mutated or partially or completely deleted in an HBV vector according to the invention.
  • a preferred HBV vector of the present invention is pHBV / V1. Its DNA sequence is shown in Fig. 1. The genes for the polymerase, the surface proteins and the capsid proteins of HBV are completely deleted in pHBV / V1. The gene for the HBV transactivator also has an ocher mutation. pHBV / V1 was deposited with the DSM (German Collection of Microorganisms and Cell Cultures) under DSM 9947 on May 3, 1995.
  • a foreign DNA can be inserted in an HBV vector according to the invention and this can then be expressed in the cells which take up the HBV vector.
  • a foreign DNA can be any DNA, in particular a diagnostically and / or therapeutically active gene.
  • the length of the foreign DNA can vary, but it is advantageous if it does not exceed about 3 kb. At the protein level, this length corresponds to a molecular weight of more than 100,000, which is sufficient for gene therapy applications.
  • the insertion of a foreign DNA into an HBV vector according to the invention takes place via the "multiple cloning site" of the latter. It is also possible to insert the foreign DNA between two inverse terminal repetitions of adeno-associated viruses. This would increase the integration frequency as well as the integration specificity of the foreign DNA in a special chromosome.
  • Another object of the present invention is a method for providing the above HBV vectors.
  • the defect in the independent replication of an HBV vector according to the invention is overcome by transfecting it into cells which express HBV functional proteins.
  • the expression of the HBV proteins can be transient and / or stable, with stable expression being preferred.
  • HBV vectors are prepared as DNA molecules as well as virus particles by the method according to the invention posed.
  • Hep G2 cells see Knowles, B.B. et al., Science 209, (1980), 497-499
  • expression plasmids which code for functional HBV proteins. It is particularly favorable if the genes for the individual functional HBV proteins are present on different expression plasmids.
  • HBV vectors which have selection markers and to delete the epsilon region necessary for packaging and various functional HBV genes in them.
  • the DNA sequence of HBV, including the epsilon region, is known (see, for example, Fujiyama, A. et al., Nucl. Acids Res. 13, (1983), 4601-4610; Polack, JR and Ganem, D. , J. Virol. 67, (1993), 3254-3263).
  • hepatoma cells e.g. Hep G2 cells
  • conventional methods can be used.
  • a transient expression of the functional HBV proteins e.g. a DEAE dextran method (cf. McCutchan, J.H. and Pagano, J.S., J. Natl. Cancer Inst. 41, (1968), 351-357)
  • stable expression e.g. a calcium phosphate precipitation method (cf. Graham, F.L. and van der Eb, A.J., Virology, 52 (1973), 456-467) is to be mentioned.
  • Cells are obtained which express HBV functional proteins. Such cells are also the subject of the present invention. Of these, preference is given to those which express, in particular stably, express the polymerase, the surface antigens and the capsid proteins of HBV.
  • the present invention provides a gene transfer system that is liver cell-specific and is suitable for gene therapy, in particular in vivo gene therapy.
  • the gene transfer system includes HBV vectors and cells, in to which these vectors can be provided.
  • the present invention makes it possible to transfer foreign DNA into liver cells and to express them there. It not only opens up possibilities for the treatment of monogenic metabolic defects, for example familial hypercholesterolemia, hyperamonaemia, hyperbilirubinemia, phenylketonuria, ⁇ 1 -antitrypsin deficiency, hemophilia, etc., but also for the therapy of multifactorial diseases, such as viral hepatitis, for example HBV, HCV, HDV , and last but not least, primary liver cell carcinoma.
  • monogenic metabolic defects for example familial hypercholesterolemia, hyperamonaemia, hyperbilirubinemia, phenylketonuria, ⁇ 1 -antitrypsin deficiency, hemophilia, etc.
  • multifactorial diseases such as viral hepatitis, for example HBV, HCV, HDV , and last but not least, primary liver cell carcinoma.
  • the present invention enables the liver to be used as a bioreactor for the secretion of any therapeutic protein into the blood. This results in new aspects of gene therapy that go far beyond the original target organ, such as the therapy of malignant diseases, viral infections or, in general, diseases that do not manifest in the liver.
  • an HBV vector according to the invention provided with a Minotor gene, can be added to the body fluid before the start of the method and then determined at certain time intervals.
  • the present invention is therefore particularly suitable as a reagent for diagnosis and / or therapy.
  • the figure shows the DNA sequence of an HBV vector according to the invention, pHBV / - V1.
  • This DNA sequence includes the following: Nucleotide No. elements
  • the remaining nucleotides include those of the cloning vector pSPT 19 (cf. Example 1).
  • Example 1 Construction of an HBV vector according to the invention, pHBV / V1
  • a 621 bp BamHI / Stu I fragment of adr 4 was excised from the plasmid pBRHBadr4 (cf. Fujiyama, A. et al., Above), which contains an HBV subtype, adr 4, and was inserted into the BamHI / Sma I opened cloning vector pSPT 1 9 (see catalog by Boehringer Mannheim, order no. 90981 5).
  • the plasmid pSPT 0.2x HBV was obtained. This plasmid contains all the regulatory elements of the E II / C p region necessary for HBV replication.
  • the plasmid pSPT 1 .2x HBV was obtained.
  • the above regulatory elements of the E II / C p region are present at the 5 'end and also at the 3' end of the HBV portion.
  • an ocher mutation in codon 8 was inserted into the X-ORF (see above) of pSPT 1 .2x HBV.
  • the plasmid pSPT 1 .2x HBV Mx was obtained.
  • HBV vector pHBV / VI
  • a known foreign DNA was inserted into the "multiple cloning site" of pHBV / V1 from Example 1. This was the luciferase gene or the LacZ gene fragment. In the first case the plasmid pV1 / HBV-Luc was obtained and in the second the plasmid pV1 / HBV-LacZ. Both plasmids were used for transient transfection of HepG2 cells (see above).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un vecteur du virus de l'hépatite B dans lequel les gènes fonctionnels du virus de l'hépatite B sont au moins partiellement effacés, ainsi qu'un procédé de production de ce vecteur du virus de l'hépatite B et des cellules utilisables à cet effet.
EP96914852A 1995-05-12 1996-05-09 Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci Withdrawn EP0826062A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19517532 1995-05-12
DE19517532A DE19517532C2 (de) 1995-05-12 1995-05-12 HBV-Vektoren und Zellen zu ihrer Bereitstellung
PCT/DE1996/000807 WO1996035797A1 (fr) 1995-05-12 1996-05-09 Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci

Publications (1)

Publication Number Publication Date
EP0826062A1 true EP0826062A1 (fr) 1998-03-04

Family

ID=7761799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96914852A Withdrawn EP0826062A1 (fr) 1995-05-12 1996-05-09 Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci

Country Status (6)

Country Link
US (1) US6623951B1 (fr)
EP (1) EP0826062A1 (fr)
JP (1) JPH11505114A (fr)
CA (1) CA2220910A1 (fr)
DE (1) DE19517532C2 (fr)
WO (1) WO1996035797A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092638A1 (en) * 2007-09-14 2009-04-09 Institut Pasteur And Inserm Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4315689A (en) * 1988-08-16 1990-03-23 Fox Chase Cancer Center Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders
DE69122098T2 (de) 1990-04-20 1997-02-20 Gen Hospital Corp Methoden zur verhinderung von viralen replikationen
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9635797A1 *

Also Published As

Publication number Publication date
JPH11505114A (ja) 1999-05-18
DE19517532A1 (de) 1996-11-14
US6623951B1 (en) 2003-09-23
CA2220910A1 (fr) 1996-11-14
DE19517532C2 (de) 1999-10-28
WO1996035797A1 (fr) 1996-11-14

Similar Documents

Publication Publication Date Title
DE69331194T2 (de) Adeno assozierter virus mit umgekehrten terminal repeat sequenzen als promotor fur den in vivo transfer eines funktionellen cftr gens
DE69535540T2 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
DE69532679T2 (de) Methode zur herstellung einer menschlichen neuralen zelllinie
EP0694071B1 (fr) Adenovirus pour le transfert d'adn etranger dans des cellules eucariotes superieures
DE69534618T2 (de) Verfahren zur herstellung rekombinanter adeno-associated viren (aav) und deren verwendung
DE69637432T2 (de) Adenovirale vektoren für die gentherapie
DE60034478T2 (de) Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
DE69433592T2 (de) Die erzielung hoher titer des rekombinanten aav-vektors
DE60129229T2 (de) Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren
DE60305443T2 (de) Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
EP0043075A2 (fr) Procédé pour augmenter l'incorporation et l'expression de matériel génétique dans les noyaux de cellules intactes à l'aide de liposomes
DE69616559T2 (de) Hilfsvirus für die herstellung von rekombinanten virusvektoren
DE69836139T2 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69535155T2 (de) Für gdnf-kodierende rekombinante adenoviren
WO1997032989A2 (fr) Systeme de transduction a base de vecteur aav recombine et son utilisation
DE69839403T2 (de) Adenovirale vektoren und eine methode zur reduktion von homologer rekombination
DE69828167T2 (de) Rekombinante adenovirale vektoren, die eine spleissequenz enthalten
DE69804463T2 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
DE69624355T2 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
EP0904394A1 (fr) Virus celo
DE69432856T2 (de) Zufuhr von genprodukten mittels mesangium-zellen
EP0746624B1 (fr) Vecteur pour l'expression specifique du foie
DE69122098T2 (de) Methoden zur verhinderung von viralen replikationen
EP0839205A1 (fr) Vecteur d'expression d'adenovirus hepato-specifique
WO1996035797A1 (fr) Vecteurs du virus de l'hepatite b et cellules permettant de produire ceux-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONDOGEN GMBH

17Q First examination report despatched

Effective date: 20031010

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031202